Metastatic Castration-Resistant Prostate Carcinoma Clinical Trials

7 recruitingLast updated: June 17, 2026

There are 7 actively recruiting metastatic castration-resistant prostate carcinoma clinical trials across 1 country. Studies span Phase 1, Phase 2, Phase 3, Phase 4. Top locations include New York, New York, United States, Orange, California, United States, Detroit, Michigan, United States. Updated daily from ClinicalTrials.gov.


Metastatic Castration-Resistant Prostate Carcinoma Trials at a Glance

7 actively recruiting trials for metastatic castration-resistant prostate carcinoma are listed on ClinicalTrialsFinder across 6 cities. The largest study group is Phase 1 with 3 trials, with the heaviest enrollment activity in New York, Orange, and Detroit. Lead sponsors running metastatic castration-resistant prostate carcinoma studies include Brigham and Women's Hospital, National Cancer Institute (NCI), and Alliance for Clinical Trials in Oncology.

Browse metastatic castration-resistant prostate carcinoma trials by phase

Treatments under study

About Metastatic Castration-Resistant Prostate Carcinoma Clinical Trials

Looking for clinical trials for Metastatic Castration-Resistant Prostate Carcinoma? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Castration-Resistant Prostate Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Castration-Resistant Prostate Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 3

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

Stage IVB Prostate Cancer AJCC v8Metastatic Prostate AdenocarcinomaMetastatic Castration-Resistant Prostate Carcinoma
Alliance for Clinical Trials in Oncology1,524 enrolled98 locationsNCT07200830
Recruiting
Phase 1Phase 2

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Stage IVB Prostate Cancer AJCC v8Metastatic Malignant Neoplasm in the BoneMetastatic Castration-Resistant Prostate Carcinoma+1 more
National Cancer Institute (NCI)90 enrolled32 locationsNCT04071236
Recruiting
Phase 1Phase 2

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Castration-Resistant Prostate CarcinomaStage IV Prostate Cancer AJCC v8Metastatic Castration-resistant Prostate Cancer+4 more
Vadim S Koshkin30 enrolled1 locationNCT05113537
Recruiting
Phase 2

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

Stage IVB Prostate Cancer AJCC v8Metastatic Castration-Resistant Prostate Carcinoma
University of Washington51 enrolled3 locationsNCT06526299
Recruiting
Phase 1

Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer

Metastatic Castration-resistant Prostate Cancer (CRPC)Metastatic Castration-Resistant Prostate Carcinoma
TechnoGenesys, Inc.40 enrolled1 locationNCT06705686
Recruiting
Phase 4

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Castration-Resistant Prostate Carcinoma
Brigham and Women's Hospital30 enrolled2 locationsNCT06099093
Recruiting

SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

Metastatic Castration-Resistant Prostate Carcinoma
University of Michigan Rogel Cancer Center60 enrolled1 locationNCT07096999